title: [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? Yes].
authors.affiliation: Klinische Abteilung für Onkologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz.
authors.forename: H
authors.initials: H
authors.lastname: Stöger
mesh_terms: D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000145:classification / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D049109:Cell Proliferation; D017024:Chemotherapy, Adjuvant; D005260:Female; D005819:Genetic Markers / Q000235:genetics*; D006801:Humans; D019394:Ki-67 Antigen / Q000235:genetics; D009376:Neoplasms, Hormone-Dependent / Q000145:classification / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D011237:Predictive Value of Tests; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D011960:Receptors, Estrogen / Q000235:genetics; D011980:Receptors, Progesterone / Q000235:genetics; D059467:Transcriptome / Q000235:genetics*
chemical_list: D005819:Genetic Markers; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human